Verition Fund Management
CRVS icon

Verition Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Verition Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,382
Closed -$165K – 2543
2025
Q4 		$165K Buy
+21,382
New +$169K ﹤0.01% 3232
2025
Q2 		– Sell
-24,413
Closed -$77.6K – 3670
2025
Q1 		$77.6K Buy
+24,413
New +$115K ﹤0.01% 3176
2021
Q3 		– Sell
-41,788
Closed -$112K – 1974
2021
Q2 		$112K Buy
+41,788
New +$115K ﹤0.01% 1705
2020
Q4 		– Sell
-146,730
Closed -$588K – 1153
2020
Q3 		$588K Buy
+146,730
New +$586K 0.01% 517

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Verition Fund Management's CRVS Position: Q1 2026 in Review

Verition Fund Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 21,382 shares — an estimated $165K sold.

Verition Fund Management first reported a position in CRVS in Q3 2020 and held it in 4 quarters. The position peaked at $588K in Q3 2020. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Verition Fund Management reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 21,382 Corvus Pharmaceuticals shares in Q1 2026, an estimated $165K.
  • Verition Fund Management first reported a position in Corvus Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Verition Fund Management's Corvus Pharmaceuticals position peaked at $588K in Q3 2020.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.